insights_auto
Pourquoi NTLA a-t-elle augmenté de 5,34%?
Approfondirchevron_right
NTLA:NASDAQ
Intellia
12,03Â $US
arrow_upward
+5,34%(+0,61) 1J
12,02Â $US
arrow_downward
-0,08% (-0,0100)bedtimeAprès clôture
Fermé : 29 sept., 16:00:00 UTC−4 · USD
search
Tous les symboles
1J
5J
1M
6M
Depuis début année
1AN
5ANS
MAX
| Symbole | Cours | Variation | % variat. |
|---|
insights_autoGénération des principaux insights pour NTLA...
Ouverture
11,49Â $US
Élevé
12,05Â $US
Faible
11,42Â $US
Cap. boursière
1,69Â Md
Vol. moyen
3,81Â M
Volume
5,01Â M
+Â haut sur 1Â an
28,24Â $US
+Â bas sur 1Â an
7,95Â $US
BPA
-3,36Â $US
Bêta
1,82
Actions en circulation
140,13Â M
Nombre d'employés
377
Ouverture
11,49Â $US
Élevé
12,05Â $US
Faible
11,42Â $US
Cap. boursière
1,69Â Md
Vol. moyen
3,81Â M
Volume
5,01Â M
+Â haut sur 1Â an
28,24Â $US
+Â bas sur 1Â an
7,95Â $US
BPA
-3,36Â $US
Bêta
1,82
Actions en circulation
140,13Â M
Nombre d'employés
377
Articles
Sources : Web et partenaires du secteur de l'information
Yahoo Finance
·
il y a 8 heures
Temporary Weakness in Intellia Stock Seems Like a Buying Opportunity
Yahoo Finance
·
il y a 2 jours
Could This Cathie Wood Stock Soar in 2027?
Seeking Alpha
·
il y a 2 jours
Intellia Therapeutics Bears Growl Again, This Time About Claude AI -- Yawn! (NASDAQ:NTLA)
Profil
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases.
The CRISPR gene editing system was originally invented by Jennifer Doudna, one of Intellia's scientific founders, and Virginijus Šikšnys. The company has entered into a number of different research and development collaborations with leading and emerging biotechnology companies including Novartis, Regeneron, Avencell, SparingVision, Kyverna, and ONK Therapeutics.
Intellia has two in vivo programs in ongoing clinical trials. NTLA-2001 is an investigational CRISPR therapy candidate for the treatment for ATTR amyloidosis currently in Phase 1 studies. Wikipedia
À propos de Intellia
PDGJohn Leonard
Employés377
Date de création2014
Siège socialCambridge, Massachusetts, États-Unis
Secteur-
Site Webintelliatx.com